What Does "230" Indicate in the HA-230 Hemoperfusion Cartridge?
The "230" in HA-230 refers to the cartridge's surface area specification of 230 cm² of adsorptive resin material.
Understanding HA-Series Cartridge Nomenclature
The HA-series hemoperfusion cartridges use a numerical designation system where the number indicates the surface area of the adsorptive material contained within the device. This is a standard naming convention used by the manufacturer (Jafron/Zhuhai Lizhu) to differentiate cartridge sizes and capacities.
Available HA-Series Cartridges
The evidence demonstrates multiple cartridge variants in clinical use:
- HA130: 130 cm² surface area - smaller cartridge for lower body weight patients or specific applications 1
- HA230: 230 cm² surface area - standard adult cartridge 2, 3, 1, 4
- HA330: 330 cm² surface area - larger cartridge for enhanced clearance capacity 3
- HA380: 380 cm² surface area - highest capacity cartridge 5
Clinical Implications of Surface Area
The surface area directly correlates with the cartridge's adsorptive capacity and clearance potential. Research shows that larger surface area cartridges (HA330, HA380) provide greater clearance capacity compared to smaller variants 3, 5.
For example, in triglyceride removal studies, the HA330 demonstrated higher mean clearance capacity (0.34 ml/min) compared to HA230 (0.01 ml/min), though both showed limited efficacy for this specific application 3.
Clinical Outcomes by Cartridge Type
Evidence from maintenance hemodialysis patients indicates that HA230 cartridges specifically reduced the risk of protein energy wasting (HR=0.30,95%CI: 0.15-0.63) and improved survival rates compared to other cartridge types 1. This suggests the 230 cm² surface area provides an optimal balance between adsorptive capacity and clinical safety for certain applications.
Important Clinical Considerations
The HA230 cartridge has been associated with increased bleeding risk in acute poisoning cases 4. Organophosphorus pesticide poisoning combined with HA230 use and prolonged activated partial thromboplastin time (≥35 seconds at 2 hours) were identified as independent risk factors for hemorrhagic complications. Close monitoring of coagulation parameters and judicious anticoagulation dosing is essential when using this device.
The cartridge selection should be based on patient body weight, the specific toxin or substance requiring removal, and institutional protocols for hemoperfusion therapy.